SPAC Market Future Outlook: The Evolution of the Blank-Check Ecosystem After 2025

The SPAC ecosystem is undergoing its most consequential structural recalibration since the SEC’s April 2021 accounting guidance on warrant liabilities triggered a wave of restatements. The catalyst for the current phase is not a single regulatory broadside but a convergence of three forces: the SEC’s proposed rule amendments under the Investment Company Act of 1940, a persistent de-SPAC failure rate exceeding 60% on a two-year post-completion basis, and the emergence of a new class of “accretive SPACs” structured to acquire operating businesses with proven cash flows rather than speculative growth narratives. For CFOs and sponsors evaluating the NYSE or Nasdaq listing path, the blank-check vehicle is no longer a shortcut to a public listing—it is a bespoke M&A instrument that demands structural precision from the trust deed to the redemption mechanics.

The Regulatory Reset: SEC Rulemaking and Market Adaptation

The Investment Company Act Overhang

The SEC’s March 2024 proposal to subject SPACs to the Investment Company Act of 1940 if they hold more than 40% of trust assets in cash or cash equivalents for more than 18 months has fundamentally altered the timeline calculus for sponsors. Under the proposed rule, a SPAC that fails to complete a business combination within 18 months of its IPO—or that holds cash-equivalent assets exceeding 40% of total trust assets after that period—must register as an investment company, triggering compliance obligations under the 1940 Act that most blank-check vehicles are not structured to satisfy. The SEC’s 2024 data shows that 47% of SPACs that went public between January 2021 and December 2023 held over 60% of trust proceeds in U.S. Treasury money market funds at the 15-month mark, placing a significant cohort directly in the crosshairs of the proposed rule.

Simultaneously, the SEC’s proposed amendments to Rule 419 and the adoption of new Rule 14a-8(f) have compressed the permissible range of sponsor promote structures. The traditional 20% promote—where sponsors receive 20% of the post-IPO equity for a nominal capital contribution—is now under direct pressure. Data from SPAC Research indicates that the average sponsor promote for SPACs announcing de-SPAC transactions in Q1 2025 fell to 14.3%, down from 18.1% in Q1 2023 and 22.4% in the peak 2021 cohort. Hong Kong-based sponsors structuring SPACs for Asian targets have been particularly active in this recalibration, with a notable shift toward earn-out-based promotes tied to post-combination share price performance over a 12- to 24-month period.

The Structural Evolution: From Blank-Check to Precision M&A

The Accretive SPAC Model

The most significant product innovation in the post-2025 SPAC market is the “accretive SPAC”—a vehicle structured specifically to acquire a target with positive EBITDA, a demonstrated track record of cash flow generation, and a clear path to organic growth without reliance on speculative revenue projections. Unlike the 2020-2021 vintage, where 73% of de-SPAC targets had negative EBITDA at the time of announcement per a 2023 study by the University of Florida’s Jay Ritter, the 2025 cohort shows a marked shift. Of the 28 de-SPAC transactions completed on the NYSE and Nasdaq in the first five months of 2025, 19 targets had positive EBITDA for at least the preceding two fiscal years. The median enterprise value-to-revenue multiple for these deals was 2.1x, compared to 6.8x for the 2021 vintage.

Redemption Mechanics and Trust Structuring

The redemption rate—the percentage of public shareholders who elect to redeem their shares for the trust proceeds rather than hold through the business combination—has become the single most important structural variable in SPAC execution. In 2021, the median redemption rate across all completed de-SPAC transactions was 12.4%. By 2024, that figure had risen to 38.7%, and in Q1 2025, the median redemption rate reached 44.2%, according to data compiled by SPACInsider. For sponsors targeting Hong Kong-based or PRC-based operating companies, the redemption risk is amplified by geopolitical uncertainty and the differential in valuation expectations between U.S. and Asian institutional investors. The structural response has been the emergence of “backstop” arrangements—committed capital from PIPE investors or sponsor affiliates that covers the gap between the trust proceeds and the minimum cash condition in the business combination agreement. The HKEX’s Listing Rules, specifically Chapter 18C for specialist technology companies, have provided an alternative listing pathway for some targets that would previously have considered a U.S. SPAC, but the U.S. market retains advantages in sector diversity and institutional depth.

The De-SPAC Performance Crisis

The two-year post-completion performance of SPACs from the 2020-2022 vintage has been catastrophic by any measure. A February 2025 analysis by the Harvard Law School Forum on Corporate Governance found that the median total shareholder return for de-SPAC companies that completed their business combinations between January 2021 and December 2022 was -53.4% as of December 31, 2024. This compares to a median return of -4.2% for traditional IPOs over the same period. The underperformance is most acute in the special purpose acquisition company cohort that targeted early-stage electric vehicle, battery technology, and SPAC-for-SPAC combinations. For sponsors and investors evaluating the current market, the performance data has two implications: first, the market is now pricing a significant discount into SPAC trust structures relative to traditional IPOs, and second, the due diligence burden on sponsors has increased substantially, with institutional investors demanding audited financials covering at least three fiscal years and independent third-party market assessments.

The Cross-Border Dynamic: Asian Targets and U.S. SPACs

Hong Kong and PRC Issuer Activity

Despite the geopolitical headwinds—including the PCAOB’s continued oversight of PRC-based audit firms under the Holding Foreign Companies Accountable Act—Hong Kong and PRC-based companies remain active in the U.S. SPAC market, albeit with a more selective profile. In 2024, four de-SPAC transactions involving targets with primary operations in the Greater Bay Area were completed, with a combined enterprise value of USD 3.2 billion. The targets spanned the consumer technology, healthcare services, and industrial automation sectors. The structural preference has shifted toward SPACs with Hong Kong-based sponsors or co-sponsors, who bring both regulatory familiarity and the ability to navigate the dual-listing or secondary listing pathways that many targets ultimately pursue. The HKMA’s 2023 circular on virtual asset activities and the SFC’s updated guidelines on sponsor due diligence under the Code of Conduct for Persons Licensed by or Registered with the SFC have created a parallel compliance framework that Hong Kong sponsors must reconcile with SEC requirements when structuring SPACs for Asian targets.

The SPAC-to-HKEX Dual Listing Pathway

A structural innovation gaining traction in 2025 is the “SPAC-to-HKEX” dual listing, where a company that completes a de-SPAC transaction on the NYSE or Nasdaq subsequently applies for a secondary listing on the Hong Kong Main Board under Chapter 19C of the HKEX Listing Rules. The advantage for the issuer is access to both the deep institutional pool of the U.S. market and the retail and regional investor base of Hong Kong. As of May 2025, three companies have executed this pathway, with the most recent being a BVI-incorporated healthcare services provider that completed its NYSE SPAC merger in October 2024 and received HKEX approval for a secondary listing in March 2025. The dual listing structure requires careful navigation of the SEC’s reporting obligations under the Exchange Act and the HKEX’s continuing obligations under the Listing Rules, but for companies with significant PRC revenue exposure, the Hong Kong listing provides a natural hedge against U.S. regulatory and geopolitical risk.

The Institutional Investor Re-engagement

The PIPE Market Recovery

The private investment in public equity (PIPE) market, which was essential to completing de-SPAC transactions in the 2021-2022 period, has staged a measured recovery. In Q1 2025, total PIPE capital committed to SPAC transactions reached USD 4.7 billion, compared to USD 2.1 billion in Q1 2024 and a trough of USD 1.3 billion in Q1 2023. The recovery is concentrated among institutional investors with dedicated SPAC and event-driven mandates, including multi-strategy hedge funds and asset managers that have built internal teams to evaluate SPAC trust structures. The terms have shifted decisively in favor of PIPE investors: the average discount to the 10-day VWAP for PIPE placements in SPAC transactions was 15.2% in Q1 2025, up from 8.7% in Q1 2022, and 72% of PIPE agreements in 2025 included price protection mechanisms such as reset provisions or anti-dilution adjustments.

The Warrants Market Normalization

SPAC warrants, which were a source of significant volatility and accounting complexity following the SEC’s April 2021 guidance, have normalized into a more predictable asset class. The bifurcation between public warrants and private placement warrants has narrowed, with the average spread between the two trading at 0.12 points in May 2025, compared to 0.47 points in May 2021. The accounting treatment under ASC 815-40—derivatives and hedging—remains complex, but the market has developed standardized language for warrant assumption agreements that reduces the risk of restatement. For sponsors, the key structural decision is whether to include warrants at all: in 2025, 31% of newly filed SPAC IPOs did not include a warrant component, up from 8% in 2021, reflecting the reduced investor demand for warrant-based upside and the accounting simplification benefits.

Closing: Three Actionable Takeaways for Sponsors and Issuers

First, SPACs structured with a 14% or lower promote, a 24-month trust duration, and a target with minimum USD 50 million in positive EBITDA for the preceding two fiscal years are the only cohort that has consistently achieved sub-30% redemption rates in the 2024-2025 market. Second, Hong Kong-based sponsors should prioritize SPACs that include a dual-listing pathway under HKEX Chapter 19C as a structural feature, given the demonstrated institutional appetite for this structure among Asian family offices and sovereign wealth funds. Third, PIPE investors will demand a minimum 12% discount to VWAP and price protection mechanisms for any SPAC transaction with a target enterprise value exceeding USD 500 million—terms that must be locked before the definitive business combination agreement is signed, not after. The SPAC market of 2025 is not the blank-check casino of 2021; it is a precision instrument for companies with real cash flows and sponsors with genuine operational expertise.